Expired activity
Please go to the PowerPak homepage and select a course.

Intravenous Immune Globulin Therapy for the Treatment of Primary Immunodeficiency Disorders

This activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported by an educational grant from Baxter Healthcare Corporation.


Samuel L. Aitken, PharmD, BCPS
Infectious Diseases Pharmacotherapy Fellow
Department of Clinical Sciences and Administration
University of Houston, College of Pharmacy
Houston, Texas

Eric M. Tichy, PharmD, BCPS, FCCP
Senior Clinical Pharmacy Specialist
Solid Organ Transplant
Director, PGY-2 Residency - Transplant
Yale-New Haven Hospital
New Haven, Connecticut


Eric M. Tichy, PharmD, FCCP, has disclosed the following affiliations or financial relationships with a commercial interest: receives grant/research support from Baxter Bioscience, Grifols, CSL Behring; consultant for Baxter Bioscience.

Samuel L. Aitken, PharmD, BCPS, has indicated that he has no affiliations or financial relationships with a commercial interest to disclose.

The following reviewer, Lindy Swain,PharmD, hereby states that she does not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Susanne Batesko, RN, BSN, Michele Salernitano, and Robin Carrino, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. We are committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.


acpePostgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0430-0000-14-013-H01-P
Credits: 2.0 hours (0.20 ceu)

Type of Activity: Knowledge
Media: Internet

Fee Information: There is no fee for this educational activity.
Estimated time to complete activity: 120 minutes


April 15, 2014


April 30, 2016


This accredited activity has been designed for pharmacists.


During the period April 15, 2014 through April 30, 2016, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the posttest and the evaluation form. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on Submit Posttest at the bottom of the page. Your posttest will automatically be graded. If you successfully complete the posttest (score of 70% or higher), your Statement of Credit will be made available immediately. Click on View Certificate and print the Statement of Credit for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest.


This activity is designed to inform and educate pharmacists in a variety of practice settings about the use of intravenous immune globulin for the treatment of primary immune deficiencies, including specific disease states, means of differentiating immune deficiencies from other diseases, dosage considerations, and product characteristics.


Upon completion of this activity, participants should be better able to:

  1. Identify primary immune deficiency disorders (PIDDs) and differentiate them from other conditions in which intravenous immune globulin (IVIG) is used;
  2. List the U.S. Food and Drug Administration (FDA)-approved indications for IVIG use;
  3. Select an evidence-based dosing and monitoring plan for patients receiving IVIG for the treatment of PIDDs; and
  4. Understand product characteristics that may increase the risk of adverse events in specific populations and the importance of appropriate product selection.


Please ensure the computer you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Peripherals: Computer speakers or headphones
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft Powerpoint, Flash Player & HTML5


The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC and Baxter Healthcare Corporation. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this monograph have not been evaluated by the FDA. Nutritional products discussed are not intended for the diagnosis, treatment, cure, or prevention of any disease.